KR102023559B1 - 제어형 하이드로코티손 방출 제형 - Google Patents

제어형 하이드로코티손 방출 제형 Download PDF

Info

Publication number
KR102023559B1
KR102023559B1 KR1020147025024A KR20147025024A KR102023559B1 KR 102023559 B1 KR102023559 B1 KR 102023559B1 KR 1020147025024 A KR1020147025024 A KR 1020147025024A KR 20147025024 A KR20147025024 A KR 20147025024A KR 102023559 B1 KR102023559 B1 KR 102023559B1
Authority
KR
South Korea
Prior art keywords
pharmaceutical composition
composition
hydrocortisone
weight
depression
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020147025024A
Other languages
English (en)
Korean (ko)
Other versions
KR20140121478A (ko
Inventor
히엡 후아탄
리차드 로스
마틴 휘터커
Original Assignee
다이어널 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 다이어널 리미티드 filed Critical 다이어널 리미티드
Publication of KR20140121478A publication Critical patent/KR20140121478A/ko
Application granted granted Critical
Publication of KR102023559B1 publication Critical patent/KR102023559B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J3/00—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
    • A61J3/07—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms into the form of capsules or similar small containers for oral use
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Inorganic Chemistry (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Nutrition Science (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Addiction (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020147025024A 2012-02-13 2013-02-12 제어형 하이드로코티손 방출 제형 Active KR102023559B1 (ko)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
GBGB1202433.7A GB201202433D0 (en) 2012-02-13 2012-02-13 Controlled drug release
GB1202433.7 2012-02-13
US201261599704P 2012-02-16 2012-02-16
US61/599,704 2012-02-16
US201261600958P 2012-02-20 2012-02-20
US61/600,958 2012-02-20
PCT/GB2013/050311 WO2013121184A1 (en) 2012-02-13 2013-02-12 Hydrocortisone controlled release formulation

Publications (2)

Publication Number Publication Date
KR20140121478A KR20140121478A (ko) 2014-10-15
KR102023559B1 true KR102023559B1 (ko) 2019-09-23

Family

ID=45930017

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020147025024A Active KR102023559B1 (ko) 2012-02-13 2013-02-12 제어형 하이드로코티손 방출 제형

Country Status (29)

Country Link
US (2) US9750704B2 (https=)
EP (1) EP2814469B1 (https=)
JP (1) JP6293678B2 (https=)
KR (1) KR102023559B1 (https=)
CN (2) CN110141557A (https=)
AU (1) AU2013220139B2 (https=)
BR (1) BR112014020008B1 (https=)
CA (1) CA2864031C (https=)
CY (1) CY1123202T1 (https=)
DK (1) DK2814469T3 (https=)
ES (1) ES2792069T3 (https=)
GB (2) GB201202433D0 (https=)
HK (1) HK1203824A1 (https=)
HR (1) HRP20200780T1 (https=)
HU (1) HUE048904T2 (https=)
IL (2) IL234061B (https=)
IN (1) IN2014DN06808A (https=)
LT (1) LT2814469T (https=)
ME (1) ME03742B (https=)
MX (1) MX361407B (https=)
NZ (2) NZ627468A (https=)
PL (1) PL2814469T3 (https=)
PT (1) PT2814469T (https=)
RS (1) RS60346B1 (https=)
RU (1) RU2619869C2 (https=)
SI (1) SI2814469T1 (https=)
SM (1) SMT202000286T1 (https=)
WO (1) WO2013121184A1 (https=)
ZA (1) ZA201508728B (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201202433D0 (en) 2012-02-13 2012-03-28 Diurnal Ltd Controlled drug release
US20160367755A1 (en) * 2015-06-01 2016-12-22 Massachusetts Institute Of Technology System and method for neuroendocrine control
FR3057775B1 (fr) * 2016-10-26 2018-11-02 Crossject Solution pharmaceutique d’hydrocortisone pour dispositif d’injection
KR101982287B1 (ko) * 2019-01-04 2019-05-24 (주)청아굿푸드 천연 추출물 함유 서방성 제제 및 그 제조방법
WO2022152863A1 (en) 2021-01-15 2022-07-21 Galventa Gmbh Pulsatile release caffeine formulation
US11904046B1 (en) 2022-11-14 2024-02-20 Eton Pharmaceuticals, Inc. Hydrocortisone oral liquid formulations
WO2025240605A1 (en) 2024-05-15 2025-11-20 Neurocrine Biosciences, Inc. Combination treatment

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100196427A1 (en) 2009-01-30 2010-08-05 Nitec Pharma Ag Delayed-release glucocorticoid treatment of rheumatoid arthritis by improving signs and symptoms, showing major or complete clinical response and by preventing from joint damage
US20110189293A1 (en) 2007-12-17 2011-08-04 CombinatoRx, Incoporated Therapeutic regimens for the treatment of immunoinflammatory disorders

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6013711A (ja) * 1983-06-21 1985-01-24 ザ、プロクタ−、エンド、ギヤンブル、カンパニ− コルチコステロイドを含有する浸透局所製薬組成物
US4552872A (en) 1983-06-21 1985-11-12 The Procter & Gamble Company Penetrating topical pharmaceutical compositions containing corticosteroids
GB2292079B (en) * 1994-08-12 1998-07-15 Flexpharm Ltd Coated prednisolone preparation for the treatment of inflamatory bowel disease
IL116674A (en) * 1995-01-09 2003-05-29 Mendell Co Inc Edward Microcrystalline cellulose-based excipient having improved compressibility, pharmaceutical compositions containing the same and methods for the preparation of said excipient and of solid dosage form thereof
US5686106A (en) 1995-05-17 1997-11-11 The Procter & Gamble Company Pharmaceutical dosage form for colonic delivery
KR19990077278A (ko) 1996-01-16 1999-10-25 마이클 오코넬 약물의 하부 위장관으로의 국소적 전달
DE19718012C1 (de) 1997-04-29 1998-10-08 Jenapharm Gmbh Verfahren zur Herstellung peroral anwendbarer fester Arzneiformen mit gesteuerter Wirkstoffabgabe
US6066339A (en) * 1997-10-17 2000-05-23 Elan Corporation, Plc Oral morphine multiparticulate formulation
EP1315481B1 (de) 2000-08-29 2006-12-06 Mepha AG Arzneimittel zur behandlung von darmerkrankungen
NZ527832A (en) * 2001-03-13 2006-03-31 Penwest Pharmaceuticals Co Chronotherapeutic dosage forms
DE20220917U1 (de) 2001-08-06 2004-08-19 Euro-Celtique S.A. Zusammensetzungen zur Verhinderung des Missbrauchs von Opioiden
GB0119848D0 (en) 2001-08-15 2001-10-10 Univ Sheffield Delayed and sustained drug release
PT1453487E (pt) 2001-11-23 2008-05-13 Procter & Gamble Forma de dosagem farmacêutica com revestimentos múltiplos
DE602004028497D1 (de) 2003-09-15 2010-09-16 Nycomed Gmbh Verwendung von ciclesonid zur behandlung von entzündlichen darmerkrankungen
GB0400031D0 (en) * 2004-01-03 2004-02-04 Univ Sheffield Depression treatment
SE0401031D0 (sv) * 2004-04-22 2004-04-22 Duocort Ab A new glucocorticoid replacement therapy
UA96457C2 (ru) * 2006-08-03 2011-11-10 Нитек Фарма Аг Лечение ревматоидного артрита глюкокортикоидами с отсроченным высвобождением
CN101795675A (zh) 2006-11-17 2010-08-04 达沃尔泰拉公司 使用具有Eudragit包衣的Zn/果胶珠粒进行的结肠递送
US20100209520A1 (en) 2007-03-26 2010-08-19 Hiroyuki Kubo Oral pharmaceutical preparation for colon-specific delivery
GB0817120D0 (en) 2008-09-19 2008-10-29 Diurnal Ltd Treatment of adrenal insufficiency
WO2010113177A2 (en) 2009-03-31 2010-10-07 Reliance Life Sciences Pvt. Ltd. Oral insulin delivery systems for controlling diabetes
WO2010115615A1 (en) 2009-04-07 2010-10-14 Duocort Pharma Ab Improved glucocorticoid therapy
US9284416B2 (en) * 2009-11-16 2016-03-15 Evonik Roehm Gmbh Process for converting a solid (meth)acrylate copolymer into a dispersed form by means of a dispersing agent
IT1405012B1 (it) * 2010-08-06 2013-12-16 Sofar Spa Composizioni di beclometasone dipropionato in microsfere gastroresistenti a rilascio modificato e processo per il loro ottenimento
GB201202433D0 (en) 2012-02-13 2012-03-28 Diurnal Ltd Controlled drug release

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110189293A1 (en) 2007-12-17 2011-08-04 CombinatoRx, Incoporated Therapeutic regimens for the treatment of immunoinflammatory disorders
US20100196427A1 (en) 2009-01-30 2010-08-05 Nitec Pharma Ag Delayed-release glucocorticoid treatment of rheumatoid arthritis by improving signs and symptoms, showing major or complete clinical response and by preventing from joint damage

Also Published As

Publication number Publication date
BR112014020008A8 (pt) 2018-01-23
RS60346B1 (sr) 2020-07-31
WO2013121184A1 (en) 2013-08-22
CN104105481A (zh) 2014-10-15
EP2814469A1 (en) 2014-12-24
CY1123202T1 (el) 2021-10-29
US10166194B2 (en) 2019-01-01
ME03742B (me) 2021-04-20
JP6293678B2 (ja) 2018-03-14
BR112014020008B1 (pt) 2022-05-24
CN110141557A (zh) 2019-08-20
RU2619869C2 (ru) 2017-05-18
HRP20200780T1 (hr) 2020-10-02
RU2014130866A (ru) 2016-04-10
EP2814469B1 (en) 2020-04-08
US9750704B2 (en) 2017-09-05
MX361407B (es) 2018-12-04
MX2014009716A (es) 2015-01-14
ZA201508728B (en) 2017-09-27
IL234061B (en) 2018-03-29
PT2814469T (pt) 2020-05-22
GB201302406D0 (en) 2013-03-27
CA2864031C (en) 2019-11-12
NZ715616A (en) 2017-03-31
DK2814469T3 (da) 2020-05-04
KR20140121478A (ko) 2014-10-15
IL234061A0 (en) 2014-09-30
ES2792069T3 (es) 2020-11-06
JP2015506972A (ja) 2015-03-05
US20140370113A1 (en) 2014-12-18
PL2814469T3 (pl) 2020-07-13
HUE048904T2 (hu) 2020-08-28
SI2814469T1 (sl) 2020-07-31
IN2014DN06808A (https=) 2015-05-22
GB2502402B (en) 2014-11-12
GB2502402A (en) 2013-11-27
CA2864031A1 (en) 2013-08-22
HK1203824A1 (en) 2015-11-06
IL245546A0 (en) 2016-06-30
AU2013220139B2 (en) 2017-08-31
AU2013220139A1 (en) 2014-08-07
LT2814469T (lt) 2020-05-25
SMT202000286T1 (it) 2020-07-08
US20170296475A1 (en) 2017-10-19
NZ627468A (en) 2016-02-26
GB201202433D0 (en) 2012-03-28

Similar Documents

Publication Publication Date Title
KR102023559B1 (ko) 제어형 하이드로코티손 방출 제형
KR101090719B1 (ko) 프로프라놀롤의 시간조절-지속 방출성 다중-과립형 투여 형태
KR100812832B1 (ko) 다입자 변형 방출 조성물
KR20100014629A (ko) 타크로리무스의 변형제형
EP3981390B1 (en) Lacosamide pharmaceutical composition and pharmaceutical preparation thereof
BRPI0707324A2 (pt) sistemas de fornecimento de fármaco compreendendo agente de bloqueio de serotonina 5-ht3 seletivo fracamente básico e ácidos orgánicos
KR20090029830A (ko) 소장 내에서 활성성분의 방출이 제어되는 경구투여용 약제학적 조제물 및 그의 제조방법
EP3813831B1 (en) Extended release compositions comprising trihexyphenidyl
EP3939574A1 (en) Delayed release cysteamine bead formulation
JP2005521682A (ja) 結腸放出組成物
US20250049753A1 (en) Methods and compositions for delivering mycophenolic acid active agents to non-human mammals
JP2022549137A (ja) イブジラスト経口製剤およびその使用方法
TW202302081A (zh) 納法莫司他（ｎａｆａｍｏｓｔａｔ）的改良釋放型組成物及其使用方法
JP2007531727A (ja) Ｇａｂａｂ受容体アゴニストを含有する即時放出特性および／または制御放出特性を有する薬学的剤形
TW202241412A (zh) 製劑
CN114425046A (zh) 一种盐酸地尔硫卓缓释胶囊
GB2510754A (en) Delayed release hydrocortisone composition
MX2008009616A (en) Drug delivery systems comprising weakly basic selective serotonin 5-ht3 blocking agent and organic acids
KR20080095873A (ko) 이미다졸릴알킬-피리딘의 안정한 제제

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20140904

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20180104

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20190212

Patent event code: PE09021S01D

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20190605

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20190910

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20190916

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20190917

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
PR1001 Payment of annual fee

Payment date: 20220719

Start annual number: 4

End annual number: 4

PR1001 Payment of annual fee

Payment date: 20240903

Start annual number: 6

End annual number: 6